论文部分内容阅读
目的:探讨尼莫地平治疗缺血性脑血管病的临床疗效。方法:收集我院2013年11月~2014年9月治疗的100例缺血性脑血管病患者,随机分成观察组和对照组各50例,对照组给予吸氧、休息、肠溶阿斯匹林75mg,1次/d,20%甘露醇125ml静滴,2次/d,1周后改为1次/d,5~7d后酌情减量。观察组在对照组的基础上加用尼莫地平,20~60mg,3次/d,两组均连续治疗14d。结果:观察组基本治愈22例,基本治愈率为44.0%,显著进步20例,显著进步率为40.0%,进步6例,进步率为12.0%,无变化2例,无变化率为4.0%,恶化0例,死亡0例,总有效率为96.0%;对照组基本治愈10例,基本治愈率为20.0%,显著进步12例,显著进步率为24.0%,进步12例,进步率为24.0%,无变化13例,无变化率为26.0%,恶化3例,恶化率为6.0%,死亡0例,总有效率为76.0%,观察组患者神经功能缺损评分:治疗前为(21.1±4.3)分,治疗后为(9.1±2.1);对照组患者神经功能缺损评分:治疗前为(21.1±4.2),治疗后为(12.7±3.4)分,两组治疗前后比较有显著性差异(P<0.05),观察组与对照组治疗后比较亦有显著性差异(P<0.05)。结论:尼莫地平治疗缺血性脑血管病疗效显著,患者恢复快,值得临床推广。
Objective: To investigate the clinical efficacy of nimodipine in the treatment of ischemic cerebrovascular disease. Methods: A total of 100 patients with ischemic cerebrovascular disease who were treated in our hospital from November 2013 to September 2014 were randomly divided into observation group (50 cases) and control group (50 cases). The control group was given oxygen inhalation, rest, enteric aspirin Lin 75mg, 1 / d, 20% mannitol 125ml intravenous infusion, 2 times / d, 1 week after the change to 1 / d, 5 ~ 7d after the appropriate reduction. The observation group was given nimodipine 20 to 60 mg on the basis of the control group 3 times a day for 14 days. Results: The observation group was basically cured in 22 cases, the basic cure rate was 44.0%, significant improvement in 20 cases, a significant improvement rate of 40.0%, progress in 6 cases, the rate of progress was 12.0%, no change in 2 cases, no change rate of 4.0% 0 cases of worsening, 0 cases of death, the total effective rate was 96.0%; the control group basically cured in 10 cases, the basic cure rate was 20.0%, significantly improved in 12 cases, a significant improvement rate was 24.0%, advanced 12 cases, the progress rate was 24.0% , No change in 13 cases, no change rate of 26.0%, 3 cases of deterioration, the deterioration rate of 6.0%, 0 cases of death, the total effective rate was 76.0%, the observation group patients with neurological deficit score: before treatment was (21.1 ± 4.3) (9.1 ± 2.1). The score of neurological deficit in control group was (21.1 ± 4.2) before treatment and (12.7 ± 3.4) after treatment, there was significant difference between the two groups before and after treatment (P < 0.05). There was also significant difference between the observation group and the control group after treatment (P <0.05). Conclusion: Nimodipine is effective in treating ischemic cerebrovascular disease and its recovery is rapid and worthy of clinical promotion.